Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results

Chevreaud, Olivier; Cohen, Salomon Y.; Jung, Camille; Blanco-Garavito, Rocío; Souied, Eric H.

doi:10.1007/s00417-016-3564-y

Cited by 9 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 11 ]. In studies involving ranibizumab, some studies have reported improvement in VA [ 14 , 15 ] whereas others have reported variable visual results with no correlation between change in BCVA and PED height [ 16 , 17 ]. Chan et al demonstrated improvement of visual acuity with higher doses of Ranibizumab (2 mg) at 12 months [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

Tyagi¹,

Juma²,

Hor³

et al. 2018

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundTo study the clinical outcomes of pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nAMD) in patients switched from Ranibizumab to Aflibercept.MethodsRetrospective non-comparative case series. 50 eyes with active nAMD and fovea involving PED of ≥100 μm measured manually using the caliper on the OCT, initially treated with intravitreal Ranibizumab (0.5 mg/0.05 ml) and later switched to Aflibercept (2.0 mg/0.05 ml). The outcome measures of best corrected visual acuity (BCVA), PED height, PED width and number of injections were measured at baseline and at time point of switch, 4 months, 1 year and at last follow up visit post-switch. Three paired t-tests and Pearson’s correlations were calculated to analyze variables at switch and change in variables at 1 year.ResultsAfter switch to Aflibercept, the improvement of BCVA was 1.84 (p = 0.11), 1.74 (p = 0.21) and 1.16 (p = 0.45) letters, the change in PED height was − 65.6μm (p < 0.001), − 50.64μm (p = 0.007) and − 68.48μm (p < 0.001) and the change in PED width was − 36.6μm (p = 0.514), + 29.7μm (p = 0.922) and + 118.4μm (p = 0.210) at 4 months, 1 year and the last visit respectively. There was a moderate negative correlation between reduction in PED height at 1 year after switch and PED height at the time of switch to Aflibercept (r = − 0.474, p < 0.05).ConclusionThe improvement in BCVA and change in PED width was not statistically significant however the reduction in PED height was significant after switching treatment to Aflibercept. The change in BCVA at 1 year after switch was not correlated with any of the analyzed anatomical characteristics of PED.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

Tyagi¹,

Juma²,

Hor³

et al. 2018

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…V ascularized pigment epithelial detachment (PED) is a common variant of neovascular age-related macular degeneration (AMD) and is most often associated with type 1 neovascularization (NV) previously referred to as occult choroidal neovascularization (CNV). [1][2][3][4][5][6][7][8][9][10][11] Pigment epithelial detachments can assume various morphologic configurations, and a number of different terms have been used to describe PED formation in neovascular AMD, including fibrovascular PED, vascularized serous PED (vsPED), and more recently multilayered PED. 3,[12][13][14] Type 1 NV accounts for up to 40% to 50% of newly diagnosed treatment-naïve patients with exuda-tive AMD.…”

mentioning

confidence: 99%

Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment Progression in Neovascular Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography

Hou

Dávila

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…However, not all PCV patients show this pattern of PED on OCT, and we adopted the decrease in PED height as the criteria for PED regression in those patients. Considering that PED height decreases 33 to 50% from baseline after anti-VEGF, [ 37 , 38 ] ≥ 50% decrease seemed to represent above average response. [ 39 ] Unlike PED regression on OCT, polyp regression on ICGA did not show any significant genetic association in this study.…”

Section: Discussionmentioning

confidence: 99%

Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy

et al. 2017

View full text Add to dashboard Cite

BackgroundTo investigate whether genetic risk variants for age-related macular degeneration (AMD) are associated with response to intravitreal anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV) patients.MethodsThis prospective cohort study included 95 treatment-naïve patients that underwent anti-VEGF treatment for PCV for 12 months. Patients were genotyped for 10 single nucleotide polymorphisms in eight AMD-relevant genes. Genotypic association with visual and anatomic outcome measures at 12 months after initial treatment, including mean change in best-corrected visual acuity (BCVA) and total foveal thickness, visual gain of ≥ 15 letters, dry status on optical coherence tomography (OCT), pigment epithelial detachment (PED) regression on OCT, polyp regression on indocyanine green angiography, and injection numbers, were investigated using regression models with adjustment for non-genetic covariates under additive genetic model.ResultsIn 81 patients who completed 12-month anti-VEGF monotherapy without photodynamic therapy, significant pharmacogenetic association was found between ARMS2 rs10490924 and PED regression on OCT. Proportions of PED regression were 26.4% for TT, 45.7% for TG, and 63.6% for GG genotype, showing additive effect of G allele for higher chance of PED regression (OR, 2.96; 95% CI, 1.38–6.36; corrected P = 0.043). For entire 95 patients, no significant association was found between candidate polymorphisms and receiving photodynamic therapy within 12 months.ConclusionsIn PCV patients, ARMS2 rs10490924 showed association with anatomic therapeutic response to anti-VEGF, suggesting pharmacogenetic relationship.Electronic supplementary materialThe online version of this article (10.1186/s12886-017-0631-z) contains supplementary material, which is available to authorized users.

show abstract

Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results

Abstract: Treatment with ranibizumab improved visual and anatomical outcome in nAMD patients with V-PED.

Cited by 9 publications

References 35 publications

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept

Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment Progression in Neovascular Age-Related Macular Degeneration Using Optical Coherence Tomography Angiography

Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy

Contact Info

Product

Resources

About